The HealthCare unit of Bayer (BAYRY) recently filed an application with the European Medicines Agency (EMA) seeking marketing approval for its blood thinner, Xarelto, for an additional indication in the EU. Bayer is looking to get the drug approved for treating pulmonary embolism (PE) and preventing the recurrence of deep vein thrombosis (DVT) and PE in adults. 
The HealthCare unit of Bayer has co-developed Xarelto with the Janssen Research and Development unit of Johnson & Johnson … [visit site to read more] or compare Credit Card Rewards and Best Credit Cards